This study looks at the safety and proper dose of a medicine called asciminib in children with a type of blood cancer known as Chronic Myeloid Leukemia (CML). These kids have already received one or more treatments before this study. The goal is to find out how asciminib works for young patients and how it compares to adult treatments.
The trial ID is NCT04925479. This is a Phase 1 and Phase 2 study, which means it is looking at how well the treatment works and its safety. The study is regulated by the FDA and hopes to include around 34 participants.
Who can join
Children aged 1 to under 18 can join this study if they have been treated for chronic myeloid leukemia before. They should also meet certain health criteria set by the trial team. The team will confirm who can participate.
Condition
Myeloid Leukemia, Philadelphia Positive
Age group
Child
Sex
All sexes
The study team makes the final call on eligibility.
What happens in the study
Participants will receive asciminib, which comes in two forms: a special pediatric version based on their weight and an adult version at a fixed dose. Some participants will take the pediatric version, while others will take the adult version. This study will have different phases to gather important information about how the medicine works over time.
Where
This trial is enrolling at 8 locations. Recruiting sites are listed first.
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania
Recruiting
Cinn Children Hosp Medical Center
Cincinnati, Ohio
Recruiting
Columbia University Medical Center New York Presbyterian
Elected to the National Academy of Medicine. Treats leukemia and myelodysplastic syndrome. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.
Professor and transplant specialist, UC Davis. Treats leukemia, lymphoma and multiple myeloma. The main doctor for adults with blood cancers, like leukemia, lymphoma, and myeloma. Recognized at state, national or international level.